{"filings":[{"id":1967923,"accession_number":"0001193125-26-326119","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-07-30T20:09:36+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q2 2026 revenue $85.4M, GAAP loss $1.05/share, revises FY revenue guidance to $330-340M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $85.4M, up 20.1% sequentially; GAAP gross margin 30.1%.","GAAP net loss $29.5M ($1.05 loss per share); non-GAAP loss $16.2M ($0.58 loss per share).","Repurchased 1.5M shares for $23.8M in Q2 2026.","Cash and investments $551.5M plus anticipated tax refund of ~$106.1M.","Revised annual revenue guidance to $330-340M from prior range (not disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787014,"accession_number":"0001674930-26-000028","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-06-01T23:07:35+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.","Median progression-free survival 6.7 months; median duration of response 7.4 months.","One-year overall survival rate 63.4% in target population.","Phase 3 study is planned based on these results.","Data cutoff April 16, 2026; presentation at ASCO 2026 Rapid Oral Abstract Session."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584037,"accession_number":"0001674930-26-000025","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-05-21T21:04:12+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.","Median DoR 7.4 months; 56% of responders still responding at Dec 20, 2025 cut-off; OS immature.","Favorable safety: mostly Grade 1-2 TRAEs; Grade 3-4 neutropenia, anemia, leukopenia; one Grade 5 pneumonia (Arm B).","Abstract #6020 presented at ASCO 2026 Rapid Oral Session on June 1, 2026 in Chicago.","Company notes historical standard-of-care offers ORR 5.8%-19.1% and PFS 2.3-3.7 months in R/M HNSCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443399,"accession_number":"0001193125-26-224147","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-05-14T20:27:52+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.","All four director nominees elected: Ming Hsieh, Linda Dong, Michael Nohaile, Regina Groves (each to serve until 2027 annual meeting).","Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 approved (24.5M for, 87K against).","Non-binding advisory vote on named executive officer compensation passed (19.8M for, 2.4M against, 45K abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94599,"accession_number":"0001193125-26-199061","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).","Revenue $71.1M; GAAP gross margin 30.2%, non-GAAP gross margin 32.3%.","Adjusted EBITDA loss of $15.2M in Q1 2026.","Cash, equivalents, restricted cash & marketable securities $604.7M; expects ~$106M tax refund.","Bought back ~2.6M shares for $40.1M in Q1; FY2026 revenue guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":71138000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107109,"accession_number":"0001674930-26-000012","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.","StrataDx acquired for ~$13.5M cash; Bako Diagnostics assets acquired for ~$43.4M cash.","Acquisition includes lease assignment for 29,099 sq ft lab/office in Alpharetta, GA through July 2032.","Advisors: Piper Sandler and Mintz Levin for Fulgent; EV Health Partners and Latham & Watkins for sellers.","Transaction originally announced Dec 22, 2025; closed March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107108,"accession_number":"0001193125-26-079152","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.","GAAP net loss $23.4M ($0.76 loss per share) in Q4; full-year GAAP loss $60.5M ($1.97 per share).","Non-GAAP net income $5.2M ($0.16 per share) in Q4; full-year non-GAAP income $13.2M ($0.42 per share).","Cash, equivalents, restricted cash, and marketable securities totaled $705.5M at year-end, plus $106.3M anticipated tax refund.","Adjusted EBITDA loss of $4.5M in Q4 and $9.4M for full year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":322671000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123445,"accession_number":"0001193125-25-328747","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.","Deal expected to close in first half 2026; subject to regulatory approvals and customary conditions.","Adds anatomic pathology, proprietary PCR tests, nationwide sales team, and CLIA/CAP labs in GA and MA.","Fulgent plans to leverage AI and digital pathology (Eziopath) to improve efficiency at acquired labs.","Acquisition funded from cash on hand; Fulgent notes organic double-digit growth in lab services business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123444,"accession_number":"0001193125-25-271006","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q3 revenue $84.1M (+17% YoY), raises FY guidance, non-GAAP EPS $0.14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $84.1M, up 17% YoY; raised full-year 2025 revenue guidance to $325.0M.","GAAP net loss $6.6M ($0.21/share); non-GAAP net income $4.5M ($0.14/share).","Full-year EPS guidance raised: GAAP loss ~($1.70)/share, non-GAAP income $0.30/share.","Adjusted EBITDA $0.7M; GAAP gross margin 42.2%, non-GAAP 44.3%.","Cash and short-term investments $787.7M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":239335000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123443,"accession_number":"0001193125-25-242917","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulgent reports Phase 2 FID-007 combo data: 51% ORR, PFS 7.8 months in R/M HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Phase 2 data for FID-007 + cetuximab in 1L-2L R/M HNSCC; 39 patients randomized.","Overall ORR 51% (75 mg/m2: 44%, 125 mg/m2: 59%); median PFS 7.8 months vs historical 2.3 months.","Treatment-related SAE rate 6%; no grade 3+ peripheral neuropathy; common grade 3+ events include lymphopenia (19%) and neutropenia (17%).","Data presented at ESMO 2025 on October 20; optimal dose to be determined after data maturation.","CEO Ming Hsieh cites steady advancement of FID-007 and strong momentum in precision diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140113,"accession_number":"0000950170-25-101103","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q2 core revenue $81.7M (+16% YoY); raises FY2025 guidance to $320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue $81.7M, up 16% YoY; total revenue $81.8M.","GAAP net loss $19.0M ($0.62 per share) includes one-time charge; non-GAAP net income $2.1M ($0.07 per share).","Adjusted EBITDA loss of $3.0M.","Raising full-year 2025 core revenue guidance to $320M.","Cash and investments $777.5M at June 30; repurchased ~130k shares for $2.2M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":155266000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157759,"accession_number":"0000950170-25-072676","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulgent Genetics elects directors, ratifies auditor, approves say-on-pay at 2025 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Ming Hsieh (19.3M for), Michael Nohaile (16.0M for), Regina Groves (14.3M for), Linda Marsh (13.8M for).","Deloitte & Touche ratified as independent auditor for FY2025 with 25.2M votes for, 0.1M against.","Non-binding advisory vote on executive compensation approved: 16.3M for, 3.8M against, 60k abstain.","Approximately 82% of eligible shares (25.3M of 30.9M) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157758,"accession_number":"0000950170-25-062257","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 core revenue $73.5M (+16% YoY); GAAP loss $0.37/share; reiterates FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue of $73.5M, up 16% YoY; GAAP net loss of $11.5M ($0.37 loss per share).","Non-GAAP income of $1.2M ($0.04 per share); Adjusted EBITDA loss of $2.9M.","Reiterates full-year 2025 core revenue guidance of $310M.","Cash and investments $814.6M ($26.60 per share); repurchased ~516k shares for $8.7M in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":73463000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176129,"accession_number":"0000950170-25-029510","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.","GAAP net loss of $42.7M ($1.41 per share) for FY 2024; non-GAAP income $15.0M ($0.49 per share).","Q4 2024 total revenue $76.2M; core revenue up 14% to $76.0M; GAAP loss $5.9M, non-GAAP income $1.2M.","Ended 2024 with $828.6M cash & investments ($26.87/share); cash from ops $21.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":283470000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193033,"accession_number":"0000950170-24-123681","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.","GAAP net loss $14.6M ($0.48 per share); non-GAAP net income $9.4M ($0.31 per share).","Adjusted EBITDA income $0.4M; cash and marketable securities $815.4M.","Reiterated FY2024 core revenue guidance of $280M; improved EPS guidance for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":207256000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209395,"accession_number":"0000950170-24-089587","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q2 core revenue $70.2M (+5% YoY); GAAP loss $0.29/share improves EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.0M; core revenue $70.2M (+5% YoY).","GAAP net loss $8.7M ($0.29 per share); Non-GAAP income $4.7M ($0.15 per share).","Adjusted EBITDA loss $727K; cash from ops $4.3M; cash and investments $837.9M.","Reiterates FY2024 core revenue guidance $280M; improves EPS guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":135513000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227414,"accession_number":"0000950170-24-061120","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulgent Genetics announces 2024 annual meeting voting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh (votes for ranged ~15.8M to 20.0M).","Ratification of Deloitte & Touche as auditor for FY2024 approved with 24.2M votes for.","Advisory vote on executive compensation approved with 19.8M votes for.","Approximately 82% of eligible shares (24.5M of 29.9M) present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227413,"accession_number":"0000950170-24-052481","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 2024 core revenue $63.2M (+1% YoY), GAAP loss $0.45/share, reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $64.5M; core revenue $63.2M (+1% YoY); FY2024 core revenue guidance reiterated at $280M.","GAAP net loss $13.5M ($0.45 diluted loss per share); Non-GAAP loss $269K ($0.01 per share).","Adjusted EBITDA loss $3.2M; cash from operations $7.3M in Q1.","Cash, cash equivalents, and marketable securities $846.2M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":64485000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246280,"accession_number":"0000950170-24-021645","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics reports Q4 GAAP loss $128.1M; core revenue grows 21% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year total revenue $289.2M; core revenue (ex-COVID) grew 44% to $262.1M.","Q4 total revenue $70.5M; core revenue grew 21% to $66.5M.","Q4 GAAP net loss $128.1M ($4.30 per share); non-GAAP income $8.3M ($0.28 per share).","Full year GAAP net loss $167.8M ($5.63 per share); non-GAAP loss $12.3M ($0.41 per share).","Cash and investments $847.7M as of Dec 31, 2023; repurchased 953k shares for $25.1M in FY 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":289213000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263722,"accession_number":"0000950170-23-058509","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent reports Q3 total revenue $85M, core revenue up 17% to $66M, GAAP loss $0.44/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue (ex-COVID) grew 17% YoY to $66M; total revenue $85M including $19M from COVID reimbursements.","GAAP net loss $13.1M ($0.44 EPS); non-GAAP loss $11.7M ($0.39 EPS) for Q3 2023.","Adjusted EBITDA was $18.1M; cash from operations $10.2M in the quarter.","Cash, cash equivalents, and marketable securities totaled $851M as of Sep 30, 2023.","Fulgent reiterates full-year 2023 core revenue guidance of $260M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":218708000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280932,"accession_number":"0000950170-23-038312","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q2 core revenue rises 48% to $67M; raises FY2023 guidance to $260M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $68M; core revenue $67M, up 48% YoY.","GAAP net loss $11.2M ($0.38/share); Non-GAAP loss $2.4M ($0.08/share).","Adjusted EBITDA loss $2.7M; cash flow from operations $9.7M.","Raises full-year 2023 core revenue guidance to $260M, narrows expected loss.","Cash, cash equivalents, and investments $846.8M as of June 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":134021000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299600,"accession_number":"0000950170-23-023014","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Fulgent Genetics stockholders approve 3M share increase to 2016 Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all four director nominees: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh.","Ratified Deloitte & Touche LLP as independent auditor for fiscal year 2023.","Advisory vote approved executive compensation with 18.9M for and 0.6M against.","Amended 2016 Omnibus Plan approved to increase shares reserved by 3M (10.8M for, 8.7M against).","Plan amendment adds 3M shares, representing ~10% dilution relative to 29.7M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299599,"accession_number":"0000950170-23-018076","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Q1 core revenue rises 150% to $62.7M; raises FY2023 core revenue guidance to $250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $66.2M; core revenue (ex-COVID) $62.7M, up 150% YoY, a record.","GAAP net loss $15.3M ($0.52 loss per share); non-GAAP net loss $6.5M ($0.22 loss per share).","Adjusted EBITDA loss of $7.2M for Q1 2023.","Cash, cash equivalents, and marketable securities of $867.8M as of March 31, 2023.","Raises full-year 2023 core revenue guidance to $250 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":66168000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319729,"accession_number":"0000950170-23-005124","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q4 2022 GAAP loss $0.80/share; core revenue up 97% YoY to $55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $67.7M; core revenue (ex-COVID) $55.0M, up 97% YoY.","GAAP net loss $23.8M ($0.80 per share); non-GAAP loss $14.2M ($0.48 per share).","Full year 2022 core revenue $181.5M, up 95% YoY; total revenue $619.0M.","Cash and investments $872.0M as of Dec 31, 2022; repurchased 815k shares in Q4.","Full year GAAP net income $143.4M ($4.63 per share); adjusted EBITDA $257.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":618968000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319728,"accession_number":"0000950170-23-000716","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Fulgent Genetics extends HQ lease by one year at $24,885/month","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lease amendment extends headquarters lease from Jan 31, 2023 to Jan 31, 2024.","Monthly rent set at $24,885 for the extended term; plus utilities and maintenance.","Fulgent Therapeutics LLC (subsidiary) amended lease with landlord E&E Plaza LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319727,"accession_number":"0000950170-23-000048","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Fulgent Genetics appoints Reggie Groves to board, cures Nasdaq audit committee deficiency","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Reggie Groves appointed to Fulgent Board effective Jan 3, 2023; serves on Audit, Compensation, and Nominating/Governance committees.","Appointment resolves non-compliance with Nasdaq Rule 5605 requiring three independent directors on Audit Committee (disclosed Nov 18, 2022).","Groves brings 13 years at Medtronic and experience as CFO/COO at Stimwave, CEO at REVA Medical, and board service at AtriCure.","Groves will receive standard compensation per Non-Employee Director Compensation Policy and entered indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337946,"accession_number":"0000950170-22-025666","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Fulgent Genetics receives Nasdaq non-compliance letter for audit committee shortage; cure period to Oct 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter Nov 18, 2022: audit committee has 2 independent directors instead of required 3.","Cure period expires at earlier of next annual meeting or Oct 31, 2023; if meeting before May 1, 2023, then May 1, 2023.","Company plans to appoint an additional independent director to regain compliance.","No immediate impact on listing or trading of FLGT common stock on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337945,"accession_number":"0000950170-22-022604","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q3 core revenue up 110% to $56M; acquires Fulgent Pharma for ~$100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 revenue $105.7M (down 54% YoY due to COVID decline); GAAP EPS $0.06, non-GAAP EPS $0.32.","Core revenue (ex-COVID) grew 110% YoY to $56.0M; adjusted EBITDA $19.7M.","Acquired Fulgent Pharma for ~$100M (cash + stock), a clinical-stage therapeutics company with nano-drug delivery platform.","Lead candidate FID-007 for head & neck cancer; combined company offers vertically integrated oncology precision medicine.","Cash, cash equivalents and investments of $918.0M as of Sep 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337944,"accession_number":"0000950170-22-022185","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Leonard Post Resigns from Fulgent Genetics Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leonard Post resigned as director and as Chair of the Nominating and Corporate Governance Committee on October 31, 2022.","The resignation was voluntary and effective immediately on October 31, 2022.","Post had served on the Board of Fulgent Genetics prior to his departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355293,"accession_number":"0000950170-22-019049","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John Bolger resigns from Fulgent Genetics board effective Sept 24, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Bolger resigned as director and Audit Committee Chair on Sept 24, 2022.","He also left the Compensation and Nominating & Corporate Governance Committees.","Resignation not due to any disagreement with company operations, policies, or practices.","No replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355292,"accession_number":"0000950170-22-014811","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q2 revenue $125.3M; core revenue up 102% YoY, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $125.3M (Q2 2021: $153.6M); billable tests 1.3M (vs 1.6M).","Core revenue (ex-COVID) $45.3M, +102% YoY; full-year core revenue guidance raised to $185M from $180M.","GAAP net income $11.5M ($0.37/share); non-GAAP net income $24.3M ($0.78/share); adjusted EBITDA $37.7M.","Cash & marketable securities $931M as of June 30, 2022.","Strong growth in genetic testing beyond COVID driving core revenue expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":445609000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373429,"accession_number":"0000950170-22-012382","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Yun Yen resigns from Fulgent Genetics board and committees effective June 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yen resigned from the Board, Audit, Compensation, and Nominating & Corporate Governance Committees.","Resignation effective June 25, 2022; no reason given other than personal decision.","No disagreement with company operations, policies, or practices cited in filing.","No replacement director or committee appointments announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373428,"accession_number":"0000950170-22-010338","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulgent Genetics holds 2022 annual meeting; all director nominees and proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees elected: Hsieh 15.9M for, Bolger 10.6M (5.6M withheld), Yen 12.3M, Marsh 12.9M.","Ratification of Deloitte & Touche as auditor for 2022: 21,789,084 for, 121,792 against.","Non-binding advisory approval of named executive officer compensation: 15,719,000 for, 405,690 against.","Advisory vote on frequency of say-on-pay: 16,052,536 for 1 year; board adopted one-year frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373427,"accession_number":"0000950170-22-007059","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q1 revenue $320.3M, core revenue up 59%, raises FY outlook to $660M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $320.3M (down from $359.4M Q1 2021); GAAP net income $154M ($4.93/share).","Core revenue ex-COVID NGS $25.1M (+59% YoY); billable tests ~3.2M vs 3.8M.","Non-GAAP net income $158.7M ($5.08/share); Adjusted EBITDA $213.5M.","Raises FY 2022 revenue outlook to $660M from $600M; core revenue outlook to $180M from $175M.","Cash & investments $1.1B at March 31; closed $170M acquisition of Inform Diagnostics on April 26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":320268000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373426,"accession_number":"0001564590-22-015730","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Fulgent Genetics completes $170M acquisition of Symphony Buyer via merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price of approximately $170 million, subject to customary adjustments for closing cash, indebtedness, working capital, and expenses.","Acquisition closed on April 26, 2022; Symphony becomes wholly owned subsidiary of Fulgent Genetics.","Deal originally announced via merger agreement dated April 16, 2022; stockholders of Symphony consented to the merger.","Consideration includes upfront cash per share plus contingent rights to escrow and post-closing adjustments.","Merger was effected through merger of a Fulgent subsidiary (Merger Sub) into Symphony, with Symphony surviving."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373425,"accession_number":"0000950170-22-005754","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Fulgent Genetics to acquire Inform Diagnostics for $170M; prelim Q1 revenue ~$300M, above guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Inform Diagnostics for ~$170M cash; expected to close Q2 2022, funded from cash on hand.","Preliminary Q1 total revenue ~$300M, exceeding prior guidance of $245M; core rev excl. COVID at least $22M.","FY2022 core revenue guidance raised to ~$175M from $120M, including expected acquisition contribution.","Acquisition adds pathology services (GI, derm, heme, etc.), 1,300 clients, 2,700 physicians, 300M+ covered lives.","Transaction expected to contribute to core revenue and be accretive to pro forma EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392150,"accession_number":"0001564590-22-012215","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Fulgent Genetics adopts executive clawback policy for incentive compensation misconduct","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Policy applies to Section 16 officers; covers equity awards and cash incentives granted on/after March 28, 2022.","Recoupment triggered by Committee finding of serious misconduct causing material legal/policy violation with significant harm.","No recoupment after change in control or for awards granted more than 3 years before first triggering event.","Company may also recoup compensation as required by law or exchange rules; no indemnification for recouped amounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392149,"accession_number":"0001564590-22-006243","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q4 revenue $251.7M, full year 2021 revenue $992.6M, core revenue up 236% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $251.7M; full year 2021 revenue $992.6M, up 135% year-over-year.","Core revenue (ex-COVID) rose 234% YoY to $40.1M in Q4; full year core rev $122.6M (+236%).","GAAP net income $104.3M ($3.34 EPS) in Q4; full year GAAP net income $507.4M ($16.38 EPS).","Non-GAAP income $108.7M ($3.48 EPS) in Q4; adjusted EBITDA $159.8M.","Cash, cash equivalents & marketable securities $935.5M as of Dec 31, 2021; cash from ops $77.1M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":992584000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410472,"accession_number":"0001564590-21-055725","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q3 revenue $227.9M (+124% YoY); raises FY revenue guidance to $930M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $227.9M (+124% YoY); core revenue $40.1M (+292% YoY).","GAAP net income $122.5M ($3.93 diluted EPS); non-GAAP net income $126.3M ($4.05 per share).","Adjusted EBITDA $167.3M; cash & investments $877.3M as of Sep 30, 2021.","Full-year 2021 revenue guidance raised to $930M from $800M.","Billable tests ~2.2M in Q3, more than double Q3 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":740913000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429277,"accession_number":"0001564590-21-042675","cik":1674930,"company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.","GAAP net income $79.8M ($2.59 EPS); non-GAAP net income $78.7M ($2.55 EPS); adjusted EBITDA $105.0M.","Core (NGS) revenue grew 296% YoY to $25.7M.","Acquisition of CSI Laboratories (cancer diagnostics) and commercial agreement with Helio Health via strategic investment.","Incremental controlling investment in Chinese JV FF Gene Biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":513045000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":523139470.82346386,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}